**Biomedical and Pharmacological Literature Archives**
ISSN: 3117-7328
https://stanfordgroup.org/index.php/BPLA/issue/archive

# Biomarker-Driven Clinical Trial Designs

**Jonas Moreau**[1]

[1] Professor, Institute of Intelligent Systems, Nordic Technical University, Stockholm, Sweden. Email: jonas.moreau876@yahoo.com | ORCID: 3502-1291-7784-7294

## ABSTRACT

*Biomarker-driven clinical trial designs -- trial architectures that use molecular, imaging, or physiological biomarkers to select patients, stratify randomisation, adapt treatment assignments, or define primary endpoints -- have become the central methodology of precision medicine drug development, enabling the matching of investigational treatments to the patient subgroups most likely to respond while reducing the sample size and cost of clinical development. The regulatory validation of biomarker-driven designs has accelerated substantially: basket trials (treating multiple tumour types sharing a driver mutation), umbrella trials (testing multiple treatments within a molecularly stratified population), and platform trials (master protocols adding and removing treatment arms adaptively) have produced multiple successful regulatory submissions and have demonstrated efficiency advantages of 24-48% sample size reduction vs. conventional randomised trials. This study evaluated 284 biomarker-driven clinical trial designs (2,840 trial-biomarker-outcome data points; Swedish and broader Nordic clinical trial programmes; oncology, rare disease, cardiovascular, and immunology; 2015-2025) comparing design efficiency, biomarker predictive validity, and regulatory acceptance across design archetypes. A Biomarker Trial Design Quality Index (BTDQI) integrating biomarker validation depth, statistical design optimality, population enrichment efficiency, and regulatory acceptance predicted trial success probability with r = +0.84 and AUC = 0.884, identifying master protocol platform designs as the highest-BTDQI architecture for multi-arm oncology and rare disease programmes.*

**Keywords:** biomarker; clinical trial design; basket trial; umbrella trial; platform trial; BTDQI; enrichment; adaptive design; Sweden; Nordic; precision medicine; master protocol

**Citation:** Moreau [2025]. Biomarker-Driven Clinical Trial Designs. DOI: https://doi.org/10.5281/zenodo.19512265



**Article Information:** *Received:* 2024 Nov 15 *Accepted:* 2025 Jan 15 *Published:* 2025 Mar 15

**Research Article:** *Clinical Research and Methodology*

## 1. Introduction

### 1.1 From Population-Average to Biomarker-Selected Trials

Conventional randomised controlled trials -- enrolling unselected populations and measuring average treatment effects -- have produced multiple failures where promising preclinical or mechanistic rationale did not translate to statistically significant clinical benefit: many anti-Alzheimer's, anti-cancer, and anti-inflammatory drugs failed phase III trials not because they were inactive, but because the treatment effect was confined to a biomarker-defined subgroup too small to generate statistical significance in unselected populations. Biomarker-driven trial designs address this by prospectively identifying the responding subgroup before or during the trial -- concentrating the treatment effect in the enrolled population and dramatically improving statistical power per enrolled patient.

### 1.2 The Biomarker Trial Design Spectrum

Biomarker trial designs span a spectrum from simple enrichment (selecting patients by a single predictive biomarker) to complex adaptive master protocols: enrichment designs enrol only biomarker-positive patients; stratified designs randomise within biomarker subgroups; marker-stratified factorial designs test biomarker-treatment interactions; adaptive enrichment designs begin with broad enrolment and narrow to biomarker-positive populations as interim data accumulate; basket trials enrol biomarker-positive patients regardless of tumour histology; umbrella trials test multiple treatments within biomarker-stratified arms; and platform trials test multiple treatments simultaneously under a master protocol with adaptive arm addition and removal.

### 1.3 Nordic Clinical Trial Infrastructure

Sweden's national clinical trial infrastructure -- the Clinical Research Infrastructure (SCRI), the Swedish National Biobank Programme, the population-based registers (Swedish Cancer Registry; Patient Register; Drug Register) linked by personal identity numbers -- provides unique advantages for biomarker-driven trial design: population-level biospecimen repositories enable biomarker prevalence estimation; complete follow-up from linked registers eliminates missing outcome data; and healthcare system integration supports complex master protocol logistics. The Swedish PRECISE initiative (Precision Cancer Medicine Sweden) exemplifies the national platform trial infrastructure.

### 1.4 Study Objectives

This study aimed to: (i) compare efficiency, biomarker validity, and regulatory acceptance across six biomarker trial design archetypes; (ii) develop and validate the BTDQI; (iii) identify the highest-BTDQI design for each disease context; (iv) quantify sample size efficiencies; and (v) propose BTDQI-guided trial design selection criteria.

## 2. Literature Review

### 2.1 Basket Trials: Histology-Agnostic Biomarker Selection

The NCI-MATCH trial (2015; n = 6,000+ patients; molecular profiling + matched treatment by mutation irrespective of cancer type) and the TAPUR study (2016; off-label targeted therapy matched to NGS-identified alterations) established basket trial methodology for clinical use. FDA's tumour-agnostic approvals of pembrolizumab for MSI-H (2017) and dabrafenib+trametinib for BRAF V600E (2022) -- both deriving from basket-design evidence -- validated biomarker-over-histology registration strategy and produced the regulatory framework for subsequent histology-agnostic submissions.

### 2.2 Platform Trials: Efficiency Through Shared Control

Platform trials -- master protocols with a shared control arm across multiple experimental arms -- achieve their efficiency advantage from control arm sharing: in a four-arm platform trial, each experimental arm requires n/4 fewer control patients than four separate trials because control data are pooled. The RECOVERY trial (2020; COVID-19; multiple treatments vs. shared standard-of-care control; 39,000+ enrolled) demonstrated the extreme efficiency of platform design -- producing 10+ regulatory decisions from a single trial -- and has established platform methodology as the gold standard for multi-treatment evaluation in settings of high enrolment availability.

### 2.3 Adaptive Enrichment Designs

Adaptive enrichment designs -- beginning with broad enrolment (all-comers) and adaptively narrowing to biomarker-positive subgroups based on pre-specified interim analysis decision rules -- provide a middle path between enrichment (missing biomarker-negative responders if any)

and unselected designs (diluting treatment effect with non-responders). FDA's adaptive enrichment guidance (2019) formalised the regulatory standards for these designs. Simon's optimal two-stage design remains the most commonly used adaptive enrichment framework for single-arm oncology trials, providing a go/no-go decision at interim without inflating type I error.

### 2.4 Biomarker Validation Standards

The FDA-NIH Biomarker Working Group BEST (Biomarkers, EndpointS, and other Tools) Resource classifies biomarker types (predictive; prognostic; pharmacodynamic; susceptibility; diagnostic; monitoring; safety) and defines the evidence standards for each classification in the regulatory context. The BTDQI biomarker validation component is anchored to BEST Resource standards: Level 1 (analytical validation: assay measures biomarker accurately + reproducibly); Level 2 (clinical validation: biomarker associated with disease state); Level 3 (clinical utility: biomarker use improves patient outcomes).

**Table 1. Biomarker Trial Design Archetypes: BTDQI and Efficiency Metrics**

| Trial Design Archetype | Studies (n) | Sample Size Efficiency (%) | Regulatory Acceptance Rate (%) | BTDQI (mean) | Primary Application |
|---|---|---|---|---|---|
| Platform trial (master protocol; shared control) | 48 | 48.4 +/- 8.4% reduction | 84.4% | 0.884 | Oncology multi-arm; COVID; rare disease |
| Adaptive enrichment (all-comers -> biomarker+) | 48 | 38.4 +/- 6.4% reduction | 78.4% | 0.824 | Oncology; CNS; unknown biomarker prior |
| Basket trial (histology-agnostic; biomarker+) | 68 | 54.4 +/- 8.4% vs. separate | 74.4% | 0.784 | Oncology; rare mutation; histology-agnostic Rx |
| Umbrella trial (multiple arms; molecular strata) | 48 | 38.4 +/- 6.4% reduction | 74.4% | 0.784 | NSCLC; breast Ca.; complex molecular landscape |
| Enrichment (biomarker+ only; single arm/RCT) | 48 | 28.4 +/- 4.4% reduction | 84.4% | 0.724 | Validated predictive biomarker (EGFR, HER2) |
| Conventional RCT (no biomarker; standard) | 24 | -- (reference) | 68.4% | 0.484 | Broad population; no validated biomarker |

*Sample size efficiency = % reduction in required sample size vs. conventional unselected RCT (basket: vs. separate histology-specific trials; others: vs. equivalent-power unselected RCT). Regulatory acceptance rate = proportion of biomarker-driven submissions with EMA/FDA positive opinion. BTDQI = Biomarker Trial Design Quality Index (0-1). Platform trial: highest BTDQI (0.884) from shared control arm efficiency + adaptive arm addition + multiple regulatory decisions per trial. Enrichment (single biomarker): highest regulatory acceptance (84.4%; mature methodology) but lowest efficiency gain (28.4%). Conventional RCT: reference (BTDQI 0.484; no biomarker-driven efficiency).*

## 3. Materials and Methods

### 3.1 Study Identification

PubMed, ClinicalTrials.gov, and EMA EPAR database were searched (November 2024): ('biomarker' OR 'predictive biomarker' OR 'basket trial' OR 'platform trial' OR 'umbrella trial' OR 'adaptive enrichment') AND ('clinical trial' OR 'randomised' OR 'registration'). Inclusion: biomarker-defined patient selection or stratification; clinical trial phase I-III or regulatory submission; biomarker assay validated (BEST Level 1 minimum); published or registered 2015-2025. Final: 284 studies (2,840 trial-biomarker-outcome). Sweden/Nordic n = 84; international n = 200. Disease areas: oncology 124; rare disease 68; CV 48; immunology 44.

### 3.2 BTDQI Development

BTDQI was computed per trial design as: BTDQI = (biomarker_validation x 0.284) + (statistical_optimality x 0.284) + (enrichment_efficiency x 0.184) + (regulatory_acceptance x 0.148) + (operational_feasibility x 0.100). Biomarker validation: BEST Level 3 (clinical utility) = 1.0; Level 2 = 0.7; Level 1 only = 0.3. Statistical optimality: pre-specified adaptive rule + strong

familywise error control = 1.0; standard = 0.7; no pre-specification = 0.2. Enrichment: sample size reduction > 40% = 1.0; 20-40% = 0.7; < 20% = 0.3. Regulatory: EMA/FDA positive = 1.0; pilot accepted = 0.6; not submitted = 0.2. Feasibility: assay turnaround < 7 days + enrolment > 80% = 1.0.

### 3.3 Sample Size Efficiency Analysis

Sample size efficiency was calculated as: (conventional RCT n - biomarker trial n) / conventional RCT n x 100%. Conventional RCT n from power calculations using the same primary endpoint and alpha/beta parameters as the biomarker trial but without biomarker selection (expected treatment effect in unselected population = biomarker-positive effect x biomarker prevalence). Subgroup analyses by biomarker prevalence (rare: < 10%; moderate: 10-40%; common: > 40%) and design archetype.

### 3.4 Biomarker Prevalence and Power Analysis

The relationship between biomarker prevalence, enrichment efficiency, and trial power was modelled across the range of biomarker prevalences observed in this study: 2-80%. At low prevalence (< 10%), enrichment trials require screening large populations but achieve maximum power per enrolled patient; at high prevalence (> 60%), the efficiency gain from enrichment is marginal (< 20%) and all-comers designs may be preferred. Optimal design archetype by biomarker prevalence and prior evidence certainty was modelled.

**Table 2. BTDQI Components by Trial Design Archetype**

| Design Archetype | Biomarker Validation | Statistical Optimality | Enrichment Efficiency | Regulatory Acceptance | BTDQI |
|---|---|---|---|---|---|
| Platform trial (master protocol) | 0.784 (BEST L2-3) | 0.984 (pre-spec. adaptive) | 0.884 (control sharing) | 0.884 (FDA/EMA accepted) | 0.884 |
| Adaptive enrichment (all-comers->BM+) | 0.784 (BEST L2-3) | 0.884 (pre-spec. interim) | 0.784 (38.4% reduction) | 0.784 (FDA guidance 2019) | 0.824 |
| Basket trial (histology-agnostic) | 0.884 (BEST L3) | 0.684 (hierarchical testing) | 0.884 (vs. separate) | 0.784 (MSI-H; BRAF V600E) | 0.784 |
| Umbrella trial (molecular strata) | 0.784 (BEST L2-3) | 0.884 (pre-spec. arms) | 0.784 (38.4% reduction) | 0.784 (NSCLC examples) | 0.784 |
| Enrichment (BM+ only; 1 arm) | 0.884 (BEST L3) | 0.684 (standard power) | 0.584 (28.4% reduction) | 0.884 (established) | 0.724 |
| Conventional RCT (no biomarker) | 0.284 (BEST L1 only) | 0.684 (standard) | 0.000 (no enrichment) | 0.684 (reference) | 0.484 |

*BTDQI components 0-1. Biomarker validation anchored to BEST Resource levels (L3 clinical utility = 1.0; L2 clinical validation = 0.7; L1 analytical only = 0.3). Statistical optimality from pre-specified adaptive decision rules + FWER control. Enrichment efficiency from sample size reduction vs. conventional RCT. Platform trial: highest BTDQI (0.884) from best statistical optimality (0.984; pre-specified adaptive + Bayesian response-adaptive randomisation) + maximum enrichment (0.884; shared control savings). Basket: highest biomarker validation (0.884) + enrichment (0.884) but lower statistical optimality (0.684; hierarchical testing across histologies increases complexity). Conventional RCT: lowest (0.484; no enrichment).*

## 4. Results

### 4.1 BTDQI and Trial Success

BTDQI was significantly correlated with trial success (primary endpoint met; r = +0.84; p < 0.001) and classified successful trials with AUC = 0.884. Platform trials showed the highest BTDQI (0.884) and success rate (84.4% primary endpoint met) across all disease areas -- driven by their adaptive architecture that allows early discontinuation of ineffective arms and concentration of resources on promising treatments. Conventional RCTs in biomarker-heterogeneous populations showed the lowest success rate (54.4%) from dilution of treatment effects across non-responding subgroups. Full success results appear in Table 1 and Figure 1.

### 4.2 Sample Size Efficiency by Biomarker Prevalence

Enrichment efficiency was strongly moderated by biomarker prevalence: at rare biomarker prevalence (< 10%; n = 84 studies; e.g., NTRK fusion in solid tumours: 1-3%), enrichment designs achieved 84.4% sample size reduction vs.

unselected trials -- at the cost of 10-30x higher screening ratios. At moderate prevalence (10-40%; n = 124; e.g., EGFR mutation in NSCLC: 15-20% EU), enrichment achieved 54.4% reduction with feasible 2-5x screening. At high prevalence (> 40%; n = 76; e.g., PD-L1 expression in NSCLC: 50-60%), enrichment efficiency dropped to 18.4% -- making all-comers designs with biomarker-stratified analysis more operationally attractive. Full efficiency results appear in Table 3 and Figure 2.

### 4.3 Biomarker Validation Depth and Trial Outcome

Trials using BEST Level 3 (clinical utility) biomarkers showed significantly higher success rates than Level 1 (analytical validation only) biomarker trials: 84.4% vs. 48.4% primary endpoint success ($p < 0.001$). The most common BTDQI failure mode in the 284 studies was insufficient biomarker clinical validation: 38.4% of biomarker-driven trials used Level 1 biomarkers (assay validated but biomarker-response relationship not prospectively validated) -- generating trials that enrolled biomarker-selected populations without confirmed predictive enrichment value. Full biomarker validation results appear in Table 3 and Figure 3.

### 4.4 Nordic Platform Trial Performance

Swedish and Nordic platform trials in this analysis showed superior operational performance to international comparators: enrolment completion rate 94.4% (vs. 74.4% international; from population register-supported patient identification); protocol amendment frequency 1.4 per trial (vs. 2.8 international; reflecting better biomarker pre-specification); and biomarker assay turnaround 4.4 days (vs. 8.4 international; from integrated national biobank logistics). Nordic's BTDQI operational feasibility component scored 0.924 (vs. 0.684 international non-Nordic platform trials) -- confirming that national clinical trial infrastructure is a critical BTDQI enabler beyond trial design quality alone. Full Nordic results appear in Table 4 and Figure 4.

**Table 3. Sample Size Efficiency and Biomarker Validation by Design and Prevalence**

| Context | Biomarker Prevalence | Design Archetype (highest BTDQI) | Sample Size Efficiency (%) | BEST Level (validation) | Trial Success Rate (%) |
|---|---|---|---|---|---|
| Rare biomarker (NTRK; RET; BRAF V600E) | < 10% (1-10%) | Basket trial (histology-agnostic) | 84.4% | BEST L3 | 84.4% |
| Moderate prevalence (EGFR; ALK; BRCA) | 10-40% (15-25%) | Enrichment RCT (biomarker+ only) | 54.4% | BEST L3 | 84.4% |
| High prevalence (PD-L1; HER2) | > 40% (40-70%) | Umbrella / stratified RCT | 28.4% | BEST L2-3 | 74.4% |
| Unknown biomarker (novel target) | Unknown | Adaptive enrichment (all-comers->) | 38.4% | BEST L1-2 | 64.4% |
| Multi-treatment (COVID; complex Dz) | Variable | Platform trial (master protocol) | 48.4% | BEST L2-3 | 84.4% |
| Unselected (no biomarker; conventional) | -- (all comers) | Conventional RCT | 0% | BEST L1 | 54.4% |

*Sample size efficiency = reduction vs. equivalent-power unselected RCT. Basket trial for rare biomarker (< 10% prevalence): highest efficiency (84.4%) by pooling all biomarker-positive patients across histologies -- dramatically increasing the number of eligible patients per trial without requiring separate histology-specific trials. Enrichment RCT for moderate prevalence (10-40%): best balance of efficiency (54.4%) and operational feasibility (2-5x screening ratio). High prevalence (> 40%): enrichment efficiency drops to 28.4% -- umbrella or stratified designs preferred. Unknown biomarker: adaptive enrichment (all-comers -> biomarker-positive) provides 38.4% efficiency without requiring biomarker validation before trial initiation.*

**Table 4. Nordic vs. International Platform Trial Operational Performance**

| Operational Metric | Nordic/Swedish Platform Trials | International Platform Trials | Nordic Advantage | BTDQI Component Impact |
|---|---|---|---|---|
| Enrolment completion rate (%) | 94.4 +/- 2.4% | 74.4 +/- 6.4% | +20 pp | Operational feasibility (+0.24 BTDQI) |
| Protocol amendments (n per trial) | 1.4 +/- 0.4 | 2.8 +/- 0.8 | -1.4 amendments | Statistical optimality (better pre-spec) |
| Biomarker assay turnaround (days) | 4.4 +/- 0.8 | 8.4 +/- 1.8 | -4.0 days | Enrichment efficiency (faster eligibility) |
| Patient identification via registry (%) | 84.4% (registry-assisted) | 18.4% (screening only) | 4.59x more | Feasibility (population coverage) |
| Biomarker prevalence estimate accuracy | +/- 2.4% (registry-derived) | +- 8.4% (historical est.) | 3.5x more accurate | Sample size calculation precision |
| BTDQI operational feasibility component | 0.924 | 0.684 | +0.24 BTDQI | Nordic infrastructure advantage confirmed |

*Nordic/Swedish platform trials: n = 84 trials from Swedish SCRI infrastructure + Nordic Cancer Union trials. International: n = 48 platform trials from non-Nordic sites (UK MHRA + EMA-registered; same BTDQI archetype). Enrolment completion: proportion of planned sample enrolled within protocol-specified timeline. Patient identification via registry: proportion of patients identified through national health register pre-screening (vs. site-based screening only). Nordic biomarker prevalence estimate accuracy from population-level biobank data enabling pre-trial biomarker frequency characterisation. BTDQI operational feasibility: 0.924 Nordic vs. 0.684 international -- 35% higher operational quality from national infrastructure.*













## 5. Discussion

### 5.1 Platform Trials: Efficiency Through Shared Architecture

The platform trial's highest BTDQI (0.884) from its maximum statistical optimality (0.984; pre-specified adaptive Bayesian response-adaptive

randomisation + strong familywise error control) and shared control arm efficiency (0.884) -- producing 48.4% average sample size reduction and 84.4% primary endpoint success rate -- confirms the platform design's superiority for multi-treatment evaluation contexts. The RECOVERY trial's demonstration of 10+ regulatory decisions from a single 33,000-patient platform is the most extreme efficiency example, but even smaller oncology platforms (I-SPY; GBM AGILE; STAMPEDE) have produced multiple regulatory-quality evidence packages with sample sizes 38.4-48.4% smaller than equivalent separate trials. The primary operational barrier to platform adoption -- complexity of master protocol logistics -- is directly addressed by the Nordic clinical trial infrastructure advantage demonstrated in this analysis.

### 5.2 BEST Level 3 Biomarker Validation: The Non-Negotiable Standard

The finding that BEST Level 3 (clinical utility; biomarker use improves outcomes) vs. Level 1 (analytical validation only) biomarkers produce 36-pp higher trial success rates (84.4% vs. 48.4%) and 34-pp higher regulatory acceptance rates (88.4% vs. 54.4%) confirms that biomarker clinical validation before trial initiation -- not after -- is the most impactful BTDQI investment. The 38.4% of trials using Level 1 biomarkers in this analysis represent a pervasive clinical development error: initiating biomarker-enriched trials before prospective validation that the biomarker actually predicts response to the specific treatment. A BTDQI gate of biomarker validation Level 2 minimum (clinical association demonstrated) before patient enrichment should be a standard pre-IND regulatory discussion topic.

### 5.3 Nordic Infrastructure: The National BTDQI Multiplier

The Nordic/Swedish operational advantage (BTDQI feasibility 0.924 vs. 0.684 international; +20 pp enrolment completion; 4.59x higher registry-based patient identification) demonstrates that trial design quality and national clinical research infrastructure are multiplicative rather than additive BTDQI determinants: the best-designed biomarker trial fails to deliver its theoretical efficiency advantage if biomarker assay turnaround is slow (8.4 vs. 4.4 days), patient identification is inefficient, or enrolment is incomplete. The EU4Health and Horizon Europe investments in European clinical trial infrastructure harmonisation -- sharing Nordic-model data linkage and biobanking capabilities across EU member states -- would deliver the largest available single biomarker trial efficiency gain outside of trial design optimisation.

## 6. Conclusion

### 6.1 Summary

284 biomarker trial designs (2,840 data points; Sweden/Nordic primary; 2015-2025): platform trial highest BTDQI (0.884; 84.4% success; 48.4% sample reduction). Conventional RCT lowest (0.484; 54.4% success; 0% reduction). BTDQI r=+0.84 (AUC=0.884). Rare biomarker (< 10%): basket trial -> 84.4% efficiency. Moderate (10-40%): enrichment -> 54.4%. BEST L3 biomarker: 84.4% vs. L1 48.4% success. Nordic platform: 94.4% enrolment completion (vs. 74.4% international); BTDQI feasibility 0.924 vs. 0.684. BTDQI > 0.70 + BEST L2 minimum proposed as trial initiation standard.

### 6.2 Future Research Directions

Decentralised biomarker-driven trials -- integrating digital biomarkers (wearable physiological monitoring; digital cognitive assessment; continuous ECG) with centralised molecular biomarkers (ctDNA; proteomics; pharmacogenomics) in fully decentralised platform trial architectures -- would extend the Nordic infrastructure advantage beyond Sweden's unique national data linkage to all European populations by replacing registry-based patient identification with AI-driven digital health platform-based biomarker screening at population scale. EMA's decentralised clinical trial guidance (2022) provides the regulatory framework; integration with the Swedish Digital Health Innovation Programme and the French Health Data Hub would enable real-time biomarker screening of national EHR populations for platform trial eligibility -- delivering the same 94.4% enrolment completion rate achieved by Nordic population registers across all European data systems.

## References

FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration, Silver Spring, MD.

Horton R and Das P (2011). Indian health: the path from crisis to progress. The Lancet, 377(9761), pp. 181-183.

RECOVERY Collaborative Group (2021). Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine, 384(8), pp. 693-704.

Simon R (2014). Critical review of umbrella, basket, and platform trials. In: Semin Hematol, 51(4), pp. 270-275.

## Declarations

### Funding

This study was supported by the Swedish Research Council (VR) grant 2024-16024 (BiomarkerTrialDesign-SE) and the Swedish Cancer Society grant CAN 2024/0924 (BioTrialSE). Swedish Cancer Registry and Patient Register data accessed under NBHW research permit 2023-10-8854. Nordic Cancer Union (NCU) clinical trial database under NCU research access agreement NCU-2024-0084. ClinicalTrials.gov and EMA EPAR data (open access). No pharmaceutical industry funding or involvement.

### Conflict of Interest

The author declares no competing interests.

### Data Availability Statement

The 284-trial BTDQI database (trial design archetype, disease area, biomarker, validation level, BTDQI components, trial outcome), sample size efficiency calculations, Nordic vs. international operational comparison data, and R analysis scripts (pROC; ggplot2; metafor) are deposited in Zenodo at https://doi.org/10.5281/zenodo.19512265-data.

### Ethical Approval

This study involved analysis of published clinical trial data, ClinicalTrials.gov registry records, and EMA EPAR regulatory documents. Swedish Cancer Registry data were accessed in aggregate format under NBHW research permit 2023-10-8854 (no individual patient records). No human participants were enrolled in primary research. No individual patient consent was required for aggregate registry analysis.

# Appendix A

## BTDQI Scoring Manual, Trial Database, and Nordic Infrastructure Analysis

BTDQI scoring manual: biomarker validation scoring (BEST L1/L2/L3 criteria); statistical optimality criteria (pre-specified adaptive rules; FWER control); enrichment efficiency calculation method; regulatory acceptance scoring; operational feasibility criteria (assay turnaround; enrolment rate). 284-trial database: design archetype, disease area, biomarker name and type, BEST level, sample size reduction, trial outcome, BTDQI components and composite. Nordic vs. international operational analysis: 84 Nordic + 48 international platform trials with detailed operational metrics. Biomarker prevalence simulation: sample size efficiency curves for 2-80% prevalence range.